Active Hepatitis B Infection

BOSTON — Triple combination of vebicorvir, imdusiran and nucleos(t)ide reverse transcriptase inhibitor did not improve markers of active hepatitis B infection in virologically suppressed patients vs. treatment regimens without vebicorvir.

May is Hepatitis Awareness Month, an annual campaign to raise awareness for viral hepatitis and its impact in the U.S. — and a month-long opening to address the importance of vaccination and testing for viral hepatitis with your patients.

According to a presenter at The Liver Meeting Digital Experience, diagnosis and treatment for hepatitis B virus remains low; therefore, significant increases in treatment are needed to decrease disease burden.

Higher end-of-treatment hepatitis B e-antigen level correlated with nucleos(t)ide clinical relapse but did not correlate with relapse severity regardless of HBsAg level among patients with chronic hepatitis B virus, according to research.

When compared with Engerix-B, a three-antigen hepatitis B vaccine candidate produced significantly high seroprotection rates in all adults, including those aged 45 years and older and those with diabetes mellitus and obesity.

A four-dose hepatitis B vaccine regimen conferred almost 90% seroprotection, established high antibody levels and was well tolerated among hemodialysis patients.

VBI Vaccines Inc. announced positive interim clinical results from an ongoing phase 1b/2a study of VBI-2601 (BRII-179), a novel recombinant, protein-based immunotherapeutic candidate for the treatment of chronic hepatitis B infection.